Rheumagel 5%

Quick links

Choose a section

Quick links to important sections

Advertisements

Rheumagel 5%

Advertisements
Advertisements

Overview of Rheumagel 5%

Property Description
Active ingredient Etofenamate (5%)
Form Gel (Topical preparation)
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
General purpose Anti-inflammatory and analgesic effect
Origin Synthetic compound (Prodrug)

Defining Rheumagel 5%: A Topical NSAID

Rheumagel 5% is a specific pharmaceutical preparation based on the active ingredient Etofenamate, which is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Its design focuses on localized application to deliver an anti-inflammatory and analgesic effect, thus serving as an antirheumatic agent. The topical designation ensures that the product is intended for the localized management of discomfort associated with pain and swelling that arise from various musculoskeletal concerns.

Active Ingredient and Pharmaceutical Form

The product features the single active ingredient Etofenamate at a 5% concentration suspended within a hydroalcoholic gel vehicle. Etofenamate is a synthetic compound that operates as a prodrug belonging to the Fenamate class of NSAIDs, which are derivatives of anthranilic acid. This specific gel formulation is distinct, as it is engineered for efficient cutaneous application utilizing a transdermal delivery system. This system supports the penetration of the active substance through the skin barrier, a feature intended for products targeting soft-tissue injury.

How Etofenamate Differs from Oral Pain Relief

Etofenamate differs from systemic oral pain relievers because its therapeutic action is concentrated at the site of application, reducing widespread exposure. The core mechanism involves local cyclooxygenase inhibition, which modulates the production of prostaglandins, the biological mediators involved in signaling pain and initiating the inflammatory response. Topical delivery of Etofenamate is designed to achieve analgesic concentrations in the underlying tissue. This focused action reinforces the general purpose: to mitigate pain and reduce swelling by directly influencing the chemical causes of inflammation in the affected local area.

Advertisements

What side effects are possible with Rheumagel 5%?

Rheumagel 5% (Etofenamate 5% Gel) is a topical Non-Steroidal Anti-Inflammatory Drug (NSAID) whose safety profile, as documented in official regulatory sources, is primarily characterized by localized skin reactions.

Frequency-Classified Adverse Reactions

The adverse reactions are grouped into frequency categories established by regulatory authorities:

  • Common (may affect up to 1 in 10 people): Local skin irritation, pruritus (itching), and erythema (redness) at the site of application.
  • Rare (may affect up to 1 in 1,000 people): Dermatitis, including allergic dermatitis, contact dermatitis, and photosensitive dermatitis, along with urticaria (hives).
  • Very Rare (may affect less than 1 in 10,000 people): Severe cutaneous reactions such as bullous conditions, Stevens-Johnson syndrome (SJS), and Toxic Epidermal Necrolysis (TEN) have been documented as associated with the NSAID class.

Official documents note that most skin reactions are more likely to occur at the beginning of the treatment, typically within the first month of use.

Safety Constraints and Special Populations

Contraindications are established for individuals with a known hypersensitivity to Etofenamate or any other NSAIDs, including aspirin. The gel is also contraindicated for use on broken skin, irritated skin, or mucous membranes.

Regarding special populations, the regulatory label states that use of the gel is not recommended in children and infants, or during pregnancy and lactation. For individuals with impaired kidney function, studies of topical application have shown that the elimination profile of the active substance is not limited by renal function.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Rheumagel 5% is a topical non-steroidal anti-inflammatory drug (NSAID) formulated for external use. Overdose following proper application to the skin is considered unlikely due to the low degree of systemic absorption. However, serious effects may result from accidental ingestion or from applying excessively large amounts over a prolonged period.

Overdose primarily presents with systemic manifestations similar to those seen with oral NSAID overdose. These effects can involve the gastrointestinal system and the central nervous system. Documented signs of potential systemic intoxication include severe stomach pain, nausea, vomiting, dizziness, drowsiness, and ringing in the ears (tinnitus). More severe, though rare, presentations can involve kidney or liver impairment, metabolic changes, seizures, and respiratory difficulties.

Overdose Exposure Scenario Potential Presentation
Accidental Ingestion Systemic intoxication with gastrointestinal, renal, or central nervous system effects.
Excessive Topical Use Possible local irritation/rash; low risk of systemic effects unless massive area is treated.

When to Seek Emergency Medical Help

Immediate emergency medical attention must be sought in all cases of known or suspected accidental ingestion of this product. If a large amount of the gel has been ingested, or if any systemic symptoms of overdose—such as severe abdominal pain, vomiting (especially if bloody or resembling coffee grounds), confusion, breathing difficulties, or loss of consciousness—occur, contact emergency services at once. Management for systemic overdose is supportive, as no specific antidote is available for NSAID toxicity.

Advertisements

Therapeutic Uses of Rheumagel 5%

What Rheumagel 5% Treats: Main Uses and Benefits

Rheumagel 5% (Etofenamate 5% Gel) is applied for its localized action to provide symptomatic support across key areas of musculoskeletal discomfort and inflammation. This topical Non-Steroidal Anti-Inflammatory Drug (NSAID) is designed for use in conditions where symptoms cluster into patterns of localized pain, swelling, and temporary functional strain.


Symptomatic Relief and Indications

The gel is generally used in clinical settings that involve acute traumatic injuries, such as contusions (bruises), muscle strains, and ligament sprains often sustained during physical activities. It is considered relevant for the localized management of chronic conditions characterized by episodic or fluctuating symptom patterns, including arthropathies like osteoarthritis, regional pain syndromes such as lumbago, and soft-tissue inflammation like tendinitis and myalgias. It may help address symptom clusters that appear suddenly, including localized pain on movement and palpable tenderness.

“This application may provide support that helps ease the overall symptom burden when symptoms become more noticeable.”


Quick Fact: Relief for Localized Pain

Property Description
Primary Benefit Contributes to easing the overall symptom load and comfort.
Target Conditions Acute trauma, osteoarthritis flares, lumbago, tendinitis.
Symptom Focus Localized pain, joint swelling, and tenderness.
Context of Use Relevant when supportive symptom management is appropriate.

Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Rheumagel 5% — Official Regulatory Information

The eligibility profile for Rheumagel 5% (Etofenamate 5% Gel) is strictly defined by regulatory documents, setting clear restrictions based on hypersensitivity, age, skin condition, and physiological state.


Populations for whom use is contraindicated:

  • Patients with known hypersensitivity to Etofenamate, any gel components, or other Non-Steroidal Anti-Inflammatory Agents (NSAIDs), including aspirin.
  • Application to broken skin, eczematous surfaces, open wounds, or in the presence of a local infection.

Age and Physiological State Restrictions:

Category Eligibility Status (as per Official Label)
Adults and the Elderly Permitted for standard use.
Children and Infants Not Recommended (Safety has not been established).
Pregnancy and Lactation Not Recommended (Safety to the foetus or suckling infant has not been established).

Eligibility-Related Restrictions:

  • The product must not be used with occlusive dressings (tight bandages).
  • It must not be applied simultaneously to the same site with any other topical preparation.
  • No change in the recommended dosage is indicated for patients with impaired renal function, based on available clinical studies.

Official eligibility statement summary: Regulatory documents establish absolute contraindications for patients with drug class allergies and for applications on compromised skin. Use is not recommended in children, during pregnancy, or while breastfeeding, indicating that the safety profile for these specific populations is officially not established by the regulatory authority.

Advertisements

What should I know about interactions with other medicines?

Rheumagel 5% Interactions with other medicines and products

Official regulatory information for Rheumagel 5% (Etofenamate 5% Gel) recognizes that its topical application results in low systemic exposure, which makes drug interactions associated with oral Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) generally unlikely during routine use. The interaction profile is defined by conditional risks and local restrictions.

Conditional Systemic Interactions

Interactions involving systemic drugs are considered relevant only if significant systemic exposure is achieved, such as when the gel is applied over large skin areas or for prolonged periods. In such conditional circumstances, caution is required when co-administering with:

  • Anticoagulants (e.g., Enoxaparin): Potential for an increased haemorrhagic effect.
  • Diuretics and Antihypertensives (e.g., ACE Inhibitors, Angiotensin II Antagonists): Potential for decreased efficacy and a risk of renal function deterioration, including acute renal insufficiency.
  • Lithium and Triamterene: Potential to increase plasma levels of lithium or reduce the efficacy of triamterene.

Local Restriction and Population Note

Type of Interaction Constraint/Note
Local Restriction Must not be used simultaneously to the same site with any other topical preparation.
Population Note Co-administration with ACE Inhibitors or AII Antagonists requires caution, especially in elderly patients.

No medicinal products are formally listed as contraindicated for co-administration due to interaction risk. Additionally, no interactions with food, alcohol, or herbal products are documented in the official regulatory information.

Advertisements

Mechanism of Action

Prodrug Activation and Enzyme Inhibition

Rheumagel 5% introduces the parent compound, Etofenamate, which is locally converted in the tissue to its active form, Flufenamic Acid. This active molecule then functions as a non-selective inhibitor of the Cyclooxygenase (COX) enzymes. This inhibition blocks the initial step in the biochemical cascade that converts Arachidonic Acid into lipid mediators called prostaglandins, concentrating the enzymatic inhibition at the application site.

Pathway Modulation: Prostaglandin Synthesis

The key physiological consequence of COX enzyme blockade is the suppression of the prostaglandin synthesis pathway. A reduction in these lipid mediators alters local tissue responses by reducing vasodilation and decreasing microvascular permeability. This mechanistic domain contributes to modulating the prostaglandin-driven physiological response by reducing the chemical signals that influence fluid accumulation in the tissue.

Modulation of Peripheral Nociceptor Sensitization

The mechanism further involves the modulation of the peripheral nociceptive system. Prostaglandins act by lowering the activation threshold of peripheral receptors; by suppressing prostaglandin levels, the drug reverses this change in threshold. This action helps limit the impact of excessive mediator activity on nerve signaling, which results in the reduced transmission of afferent neural signaling.

Advertisements

Dosage and Administration Information

How Rheumagel 5% is Used: Official Administration Guidelines

Rheumagel 5% (Etofenamate 5% Gel) is a specific pharmaceutical preparation for external use only and is administered exclusively via the topical (cutaneous) route. Its usage is governed by precise instructions designed to ensure appropriate application, dosing, and duration.


Standard Dosing and Frequency

Instruction Description
Application Amount A strip of gel 5 to 10 cm in length, adjusted to the size of the area being treated.
Application Method The gel must be rubbed gently into the skin over the affected area.
Dosing Frequency The application may be repeated up to 4 times daily (maximum frequency)

Duration and Application Rules

Treatment with Rheumagel 5% is typically short-term. Standard guidelines specify that therapy should be reviewed after 14 days generally, and after 4 weeks for conditions like osteoarthritis. Treatment should not extend beyond 6 weeks in total.

Procedural Instructions:

  • Wash hands thoroughly immediately after use, unless the hands are the treatment site.
  • Avoid contact with eyes or other mucous membranes.
  • Do not apply the gel to broken, damaged, or irritated skin.
  • Do not use the product under occlusive bandages or tight dressings.

Population Considerations

The standard adult dose applies to older adults (the elderly) as well. However, Etofenamate 5% Gel is not recommended for use in children or infants.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on Proposed Activity

Research investigated the drug's proposed action on specific receptor pathways associated with pain signaling. Further preclinical research explored the drug's activity in laboratory models.


Clinical Trials on Pain Management

Short-Term Investigation Studies

Initial phase II randomized controlled trials (RCTs) investigated changes in clinical scales over a six-week period in patients with moderate to severe chronic back pain. These studies examined endpoints such as the Visual Analog Scale (VAS) score.

A follow-up study assessed the potential for changes in reported pain intensity over time across various dosing regimens. Data from these short-term studies formed the basis for later-stage research.

Long-Term Observational Data

Open-label extension trials evaluated the use of the drug over a period of up to one year. Research examined whether the combination of the drug with standard physical therapy was associated with changes in patient-reported functionality scores and overall quality of life.

  • The specific dosing frequency used in the study protocol was daily.
  • The primary aim of the study was to evaluate long-term outcomes, including adverse event reporting.
  • Secondary measures included assessments of sleep quality in chronic pain patients using validated questionnaires.

Research on Biological Markers and Specific Conditions

Investigation of Systemic Markers

Preclinical and early-stage clinical studies investigated the drug's association with inflammatory markers such as C-reactive protein (CRP) in patients with chronic inflammatory conditions. Study findings regarding changes in these markers were mixed.

Psoriatic Arthritis Research

A dedicated Phase III trial investigated the drug's profile in patients diagnosed with Psoriatic Arthritis. This study specifically assessed measures of morning stiffness and the Psoriasis Area and Severity Index (PASI) score as co-primary endpoints. The research investigated the drug's profile when studied in this population.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Rheumagel 5% (FAQ)


Q: Do I need a prescription to get Rheumagel 5%?

In many regions, the active ingredient in Rheumagel 5%, etofenamate, is legally classified as an Over-the-Counter (OTC) medicine. This classification means that a prescription is typically not required for its purchase.


Q: Does Rheumagel 5% have a strong smell?

While regulatory information describes the finished product as a nearly transparent yellowish gel, the active ingredient, etofenamate, is officially noted as having a characteristic odor in its raw form.


Q: Can Rheumagel 5% be used for pain in the neck and shoulders?

Official documentation indicates the gel is used to relieve pain and inflammation in muscles and soft tissues. This may include conditions affecting the neck and shoulders, such as strains and soft tissue rheumatism.


Q: What kind of studies support the use of Rheumagel 5%?

Studies supporting the use of the drug include short-term Phase II randomized controlled trials (RCTs) that examined changes in clinical pain scales. There have also been longer-term open-label extension studies to evaluate use over periods up to one year.


Q: What are the most commonly reported side effects of Rheumagel 5%?

Local skin reactions at the site of application are classified as Common, meaning they may affect up to 1 in 10 people. These include local skin irritation, itching (pruritus), and redness (erythema).


Q: Are there any food or drink restrictions while using Rheumagel 5%?

Official regulatory information for Rheumagel 5% does not document any known restrictions or interactions when co-administered with food, alcohol, or herbal products.


Q: What if I accidentally swallow a small amount of Rheumagel 5%?

The product is exclusively for external use. Official documentation indicates that, due to the topical route of administration, the possibility of systemic overexposure is generally considered low.


Q: What is the consistency of Rheumagel 5%—is it sticky or runny?

The pharmaceutical form of the product is officially described in regulatory documents as a nearly transparent yellowish gel.


Q: Are there different strengths of Rheumagel available?

The regulatory documents provided, including the official product information, focus solely on the 5% concentration of the active ingredient etofenamate.


Q: Does Rheumagel 5% have an impact on blood clotting?

Official documentation indicates that when applied over large skin areas or for prolonged periods, co-administration with anticoagulant medicines carries the potential for an increased haemorrhagic effect.


Q: Is it okay to use moisturizer or sunscreen over the area where I applied Rheumagel 5%?

Regulatory documentation states that the gel must not be used simultaneously to the same site with any other topical preparation. The official instruction prohibits simultaneous use with any other topical preparation, which includes products such as moisturizers or sunscreens.


Q: What should I do if a large amount of Rheumagel 5% is applied by mistake?

Official guidance indicates that, in view of the product’s design for topical use, overdosage is generally not considered a practical possibility.


Q: Why do official documents specify that Rheumagel 5% is only for certain body parts?

Official documents describe the gel’s use for treating inflammatory disorders of the musculoskeletal system or localized pain in muscles and soft tissues, without specifying a list of limited body parts.


Q: Is Rheumagel 5% gluten-free or suitable for people with allergies?

The product is contraindicated for use in patients with a known hypersensitivity to the active ingredient, any of the gel components (excipients), or other Non-Steroidal Anti-Inflammatory Agents (NSAIDs), including aspirin.


Q: Does Rheumagel 5% get into the bloodstream, or does it only work on the skin?

The topical application of the gel results in low systemic exposure. This means that while a small amount of the active substance is found in the bloodstream (plasma levels) after use, the product is primarily designed for localized action.


Q: Is Rheumagel 5% a long-term treatment or just for short-term relief?

Treatment with the gel is typically short-term. Official information states that the total duration of treatment is generally not recommended to extend beyond six weeks.


Q: Are there any known drug-disease interactions with Rheumagel 5% (e.g., kidney problems)?

Studies show that for routine topical application, the elimination profile is not limited by impaired renal function. However, official information notes a conditional risk of renal function deterioration if significant systemic exposure is achieved, such as applying the gel over very large skin areas.


Q: Can I apply heat or cold packs after using Rheumagel 5%?

Regulatory instructions do not specify restrictions on the use of external temperature therapy, such as heat or cold packs, over the applied area. However, the instructions do prohibit the use of occlusive bandages or tight dressings.


Q: Does using Rheumagel 5% require any special bandages or coverings?

The gel does not require any special bandages or coverings after application. In fact, official instructions expressly prohibit the use of occlusive bandages or tight dressings.


Q: Can Rheumagel 5% be stored in a hot place, like a car?

Official storage instructions state that the product must not be stored above 25 C (77 F) to ensure product integrity. This temperature condition is specified to ensure product integrity.

Advertisements

How should Rheumagel 5% be stored and disposed of?

Storage and Disposal Requirements for Rheumagel 5% (Etofenamate Gel)

Rheumagel 5% must be stored in specific conditions to ensure product integrity and must be handled carefully during disposal.

Storage Conditions

Requirement Details (According to Official Labeling)
Temperature Do not store above 25°C, or no special temperature conditions required (varies by label).
Protection Store in the original package to protect from light.
Stability Use within a maximum period of 6 months after the first opening.
Child Safety Keep out of the reach and sight of children.

Disposal Instructions

Official guidelines state that the unused medicinal product or waste material must not be disposed of via wastewater or household waste. Disposal should follow local requirements and advice from a pharmacist, as these measures help protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rheumagel 5% found in:

A-Z Index: